Mo Yunfang, Wang Zejian, Gao Jian, Yan Yan, Ren Huaijuan, Zhang Fengli, Qi Nianmin, Chen Yantian
Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P.R. China.
China Stem Cell Therapy Co., Ltd., Shanghai 201203, P.R. China.
Exp Ther Med. 2021 Sep;22(3):936. doi: 10.3892/etm.2021.10368. Epub 2021 Jul 1.
Type 1 diabetes (TID) is a chronic metabolic disease where the body produces insufficient or no insulin. Stem cells with multi-directional differentiation potential are transplanted and differentiate into β-like cells to replace pancreatic β cells, which has become a novel treatment strategy. The aim of the present study was to investigate the ability of three types of adult mesenchymal stem cell (MSC) to differentiate into pancreatic β-like cells in order to identify suitable sources for the treatment of diabetes. The three MSC types were menstrual blood-derived MSCs (MENSCs), umbilical cord-derived MSCs (UCMSCs) and dental pulp MSCs (DPSCs). The differentiation method used in the present study was divided into three steps and the MSCs were differentiated into pancreatic β-like cells . Among these MSCs, MENSCs had a greater ability to differentiate into islet β-like cells , while UCMSCs and DPSCs exhibited a similar differentiation potency, which was relatively lower compared with that of MENSCs. The present results indicated that MENSCs may be a suitable cell source for the curative treatment of TID.
1型糖尿病(TID)是一种慢性代谢疾病,机体产生的胰岛素不足或完全不产生胰岛素。具有多向分化潜能的干细胞被移植并分化为β样细胞以替代胰腺β细胞,这已成为一种新的治疗策略。本研究的目的是研究三种成人间充质干细胞(MSC)分化为胰腺β样细胞的能力,以确定治疗糖尿病的合适细胞来源。这三种MSC分别是月经血来源的间充质干细胞(MENSC)、脐带来源的间充质干细胞(UCMSC)和牙髓间充质干细胞(DPSC)。本研究中使用的分化方法分为三个步骤,将MSC分化为胰腺β样细胞。在这些MSC中,MENSC分化为胰岛β样细胞的能力更强,而UCMSC和DPSC表现出相似的分化能力,与MENSC相比相对较低。目前的结果表明,MENSC可能是TID治疗的合适细胞来源。